Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis

PURPOSE: The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients with primary osteoporosis have not been well established. METHODS: We searched MedLine, EMBase, CENTRAL, CINAHL, and AgeLine prior to February 2010. Bibliographies were also searched and experts in the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, Lisa-Ann, Vogt, Kelly N, Adachi, Jonathan D, Thabane, Lehana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116803/
https://www.ncbi.nlm.nih.gov/pubmed/21691586
http://dx.doi.org/10.2147/TCRM.S19385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116803/
https://www.ncbi.nlm.nih.gov/pubmed/21691586
http://dx.doi.org/10.2147/TCRM.S19385

Ejemplares similares